Patient characteristics	TBI-based regimen (n = 28)	Non-TBI based regimen n = 32	p
Median age (range), years	28 (17-49)	32 (17-48)	0.31
Sex-ratio	1.33	3.6	0.08
Diagnosis			0.4
B-ALL, n (%)	14 (50%)	20 (62.5%)
T-ALL, n (%)	12 (43%)	10 (31.3%)
Mixed lineage leukemia, n (%)	2 (7%)	2 (6.2%)
Median time diagnosis-allo-HSCT (range), months	6 (2-137)	7 (3-41)	0.05
Disease status before transplant, n (%)			0.55
CR1	21 (75%)	26 (81%)
>CR1	7 (25%)	6 (19%)
HCT-CI score ≥ 2, n (%)	8 (28.6%)	3 (9.4%)	0.05
ABO mismatch, n (%)			0.55
Matched	18 (64.3%)	17 (53.2%)
Major or bidirectional or minor	10 (35.7%)	15 (46.8%)
Stem cell source, n (%)			0.35
Bone marrow	12(43%)	10(31%)
Peripheral blood stem cell	26(57%)	22(69%)
GVHD prophylaxis			0.92
Cyclosporine and methotrexate +/−ATG	27(96.4%)	31(96.9%)
Cyclosporine	1 (3.6%)	1 (3.1%)